Breakthrough Achievement: First mRNA RSV Vaccine Receives FDA Approval
MedPage Today) — In a groundbreaking move, the FDA has given the green light to the first-ever mRNA-1345 vaccine (mRESVIA) designed to combat respiratory syncytial virus (RSV) in adults aged 60 and older. This exciting development aims to shield seniors from serious lower respiratory tract disease, Moderna revealed Friday in an official press release